USPTO serial 79305516
HEMESIGHT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 24, 2022
- Examiner
- BURDECKI, ANNA C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with HEMESIGHT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kazuyo Morita
Kazuyo Morita Holland & Hart LLPP.O. Box 8749Attn: Trademark DocketingDenver, CO 80201Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic preparations for medical purposes for diagnosing and treating cancer through genetic testing; diagnostic reagents for medical use in diagnosing cancer | ACTIVE | — |
| 044 | Providing medical information in the field of genetic and sequencing testing for the diagnosis and treatment of cancer; medical diagnostic services in the nature of performing diagnosis of disease in the field of cancer diagnostics; medical testing for diagnostic or treatment purposes, namely, genetic testing and sequencing tests for diagnosis and treatment of cancer | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Otsuka Pharmaceutical Co., Ltd.
- Other trademarks owned by Otsuka Pharmaceutical Co., Ltd.
- Other trademarks owned by Otsuka Pharmaceutical Co., Ltd.
- Other trademarks in Class 005
- Other trademarks in Class 044
- Similar marks named HEMESIGHT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 13, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 2, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 8, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 8, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 24, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 24, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 24, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 8, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 8, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 7, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 16, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 16, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 16, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 28, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 28, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 28, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 28, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 28, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 17, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 16, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 16, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 5, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 16, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 16, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 11, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 10, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 2, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 16, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 12, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 11, 2021 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Mar 4, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |